Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Look, we believe that this business has a very unique opportunity to grow low double-digits on revenue and mid-teens plus on profitability |
| We'll continue to build on the foundation we have laid over the past several quarters to deliver long-term sustainable growth |
| Clinical services revenue increased 20% driven by strong volumes across all our modalities and another increase in revenue per test |
| We saw meaningful progress in the execution on our strategic priorities, and therefore we're able to reach the high end of our raised guidance |
| The strong growth in clinical services helped to mitigate the expected lower revenue in ADx due to a strong comparable in ADx in Q4 of 2022, as well as macro conditions in pharma sector and margin optimization initiatives that we took in 2023 |
| I'm very proud of our teams Q4 and full year progress including strong revenue growth of 16% for 2023, and significant improvement in adjusted EBITDA and cash flow from operations |
| We achieved positive EBITDA in the third quarter of 2023 and significantly improved again this quarter |
| Based on our strong performance in 2023 and our confidence in our strategic initiatives in 2024 and beyond, we are increasing our long range revenue growth target and outlying years from 7% to 9% to 10% plus in our core business excluding MRD |
| And do you think -- there's going to be some earning calls that come up in 90% of the revenues NGS, and so I think we believe very strongly in that ability, on that mix shift |
| I'm excited for our teammates and our customers, and most of all for the patients we serve on a daily basis |
| Adjusted gross profit was $264 million, representing adjusted gross margins of 44.7% and adjusted EBITDA was positive $3 million for the full year, an improvement of $51.5 million or 107% versus prior year |
| Now on Slide 6, I'm pleased that the fourth quarter continued the trend that we've seen throughout 2023, a consistent sequential improvement in revenue, adjusted gross profit, and adjusted EBITDA |
| Notably, our revenue growth has been strong each quarter of the year |
| We've built a momentum of reaching positive adjusted EBITDA in Q3 and carried that into Q4 |
| We believe that we've laid solid foundation for growth in 2023 and expect that momentum to continue as we move throughout 2024 |
| We feel very confident in our ability to manage that as it comes on |
| The more time I spend in the business, the more impressed I am with our unique competitive position in the marketplace with a breadth of cancer tests, our operational capabilities and passionate teammates that lead our business every single day |
| And so I think that we -- that's enhanced our confidence in some of these things |
| Our deep relationships with community pathologists and oncologists provide us an advantage in the market, and our focus on oncology testing has allowed us to develop extensive patient databases and relationships, and we view ourselves as a collaborative partner to pathologists, oncologists, hospitals, and biopharma companies we serve |
| Beyond these market conditions, it's a strong execution by our teammates that enable us to deliver such strong quarterly and full year results to our stakeholders |
| I think as we look at our ability to generate operating leverage on the revenue growth, it clearly will benefit our long range plan from an adjusted EBITDA and adjusted gross margin basis |
| And also, just our ability to generate operating leverage off that revenue growth, I think, will help the adjusted EBITDA growth over time as well |
| In summary, 2023 represented a strong year of execution and financial performance, which positions us well to continue to momentum in 2024 |
| Protect, expand, and acquire, which has contributed to our strong volume growth increased AUP and improved mix |
| Look, a lot will depend on what is grandfathered and what is not, but I think we feel really good about our position in the marketplace |
| Our continued improvement in turnaround time has contributed to or at -- at or above market growth rates across all modalities |
| In addition, the mix shift towards higher value modalities in tests has supported the delivery of yet another quarterly improvement in revenue per test |
| And I think over time it could have top side benefits as well as we improve our, our client service |
| As a result of our increased coverage, clinical support, and patient-centric mentality, we maintained our customer experience leadership in the market with a three point improvement in net promoter score, which is now at 70 |
| As we continue to build this business brick by brick, I am more confident in our future than ever |
| Statement |
|---|
| The expected decline in revenue was partially due to macroeconomic conditions and pharma R&D spend, as well as our decision to rationalize our global testing sites and low margin contracts |
| Turning to Slide 11, as we forecasted on prior quarterly calls, Advanced Diagnostics revenue declined 17% over the prior year in Q4, but was up 5% sequentially to $26 million |
| The headwinds that you'd be facing rationalizing some testing sites, low margin business as well as you're facing some macro conditions |
| You saw this year the significant amount of our growth drop into the bottom-line |
| Sorry, I missed that |
| I think, as that ratio increases, certainly it gets marginally harder, but I wouldn't discount the fact that we have launched new products last year |
| Chris Smith And the third one is obviously the toughest getting new customers, thus by far the biggest opportunity where we have to spend time for starting lab 12 months ago, which is just community oncologists |
| And then there's the payer policy aspects, which are a little bit harder, particularly with the larger panel test |
| Look, I think when we came in, I mean, I think the first thing is we made a very conscious decision that, that business had a lot of pieces to it that were not profitable |
| That's where today reimbursement from a third-party payer perspective is quite limited |
| But on the liquid side, especially for solid tumor and as Chris mentioned earlier, we're very much underpenetrated on the solid tumor side because we didn't have the right product mix, and now we are launching our liquid biopsy CGP, which will allow us to make that offering to pharma where they don't have tissue to give to us for samples that have been sitting around 3, 5, 10 years old from the clinical trials that have been completed |
| Therefore, we expect revenue to be down sequentially in Q1 ‘24 in a range of $148 million to $151 million, representing 8% to 10% growth over prior year, and expect our strategic initiatives to drive a higher growth rate as the year progresses |
| I don't know that it changes meaningfully when we achieve that mid-to-high teens, but it could pull it forward, I think, a period of time |
Please consider a small donation if you think this website provides you with relevant information